{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jin Y"],"funding":["the Department of Science and Technology of Sichuan Province","National Key Research and Development Program of China"],"pagination":["68"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11684065"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["21(1)"],"pubmed_abstract":["<h4>Background</h4>Pancreatic cancer is a highly aggressive tumor with a poor prognosis due to a low early detection rate and a lack of biomarkers. Most of pancreatic cancer is pancreatic ductal adenocarcinoma (PDAC). Alterations in the N-glycosylation of plasma immunoglobulin G (IgG) have been shown to be closely associated with the onset and development of several cancers and could be used as biomarkers for diagnosis. The study aimed to explore intact N-glycosylation profile of IgG in patients with PDAC and find relation between intact N-glycosylation profile of IgG and clinical information such as diagnosis and prognosis.<h4>Methods</h4>In this study, we employed a well-evaluated approach (termed GlycoQuant) to assess the site-specific N-glycosylation profile of human plasma IgG in both"],"journal":["Clinical proteomics"],"pubmed_title":["Quantitative site-specific N-glycosylation analysis reveals IgG glyco-signatures for pancreatic cancer diagnosis."],"pmcid":["PMC11684065"],"funding_grant_id":["2022YFF0608401","2021YFS0109"],"pubmed_authors":["Gu Y","Wei A","Zhang Y","Li A","Jin Y","Hu R"],"additional_accession":[]},"is_claimable":false,"name":"Quantitative site-specific N-glycosylation analysis reveals IgG glyco-signatures for pancreatic cancer diagnosis.","description":"<h4>Background</h4>Pancreatic cancer is a highly aggressive tumor with a poor prognosis due to a low early detection rate and a lack of biomarkers. Most of pancreatic cancer is pancreatic ductal adenocarcinoma (PDAC). Alterations in the N-glycosylation of plasma immunoglobulin G (IgG) have been shown to be closely associated with the onset and development of several cancers and could be used as biomarkers for diagnosis. The study aimed to explore intact N-glycosylation profile of IgG in patients with PDAC and find relation between intact N-glycosylation profile of IgG and clinical information such as diagnosis and prognosis.<h4>Methods</h4>In this study, we employed a well-evaluated approach (termed GlycoQuant) to assess the site-specific N-glycosylation profile of human plasma IgG in both","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Dec","modification":"2025-04-04T08:11:44.934Z","creation":"2025-04-04T08:11:44.934Z"},"accession":"S-EPMC11684065","cross_references":{"pubmed":["39734184"],"doi":["10.1186/s12014-024-09522-4"]}}